thebestgene.com (Bestgene Inc) provides fast, cheap and high quality Drosophila transgenic (transgene/injection/microinjection/p-element transformation) service. (Drosophila, fly, fruit fly, P-element, embryo, Transgenic, microinjectoin, injection, transformation, transgene, service, facility, research, transgene service, Drosophila transgene, fly transgene, fruit fly transgene, Drosophila injection, fly injection, fruit fly injection, Drosophila microinjection, fly microinjection, fruit fly microinjection, p-element transformation service, Drosophila embryo microinjection, embryo microinjection, transposon injection, P-element injection, transgenic fruitfly, transgenic fly, transgenic Drosophila)
Best Gene Inc | Home | Order form | Contact Us | FAQ | Login |  
Drosophila Embryo Injection Services
Search:
 
loginOrder NowMy Accountservice  

 
Log-In User ID: Password: | Forget Password | Register

 

PhiC31 integrase-mediated transgenesis systems - P[acman] and FlyC31

PhiC31 integrase-mediated transgenesis systems are based on the site-specific bacteriophage PhiC31 integrase which mediates sequence-directed, irreversible and highly efficient integration between a bacterial attachment site (attB) and a phage attachment site (attP). Injecting plasmid containing attB site and white marker into attP-containing docking site strain(s) with PhiC31 activity makes the resultant stable w+ transformants containing your gene-of-interest between attL and attR sites (irreversible).

P[acman]
P[acman] system makes use of the combined tools of a conditional amplifiable technique for typical P1 and BAC construct, recombineering, and PhiC31-mediated trangenesis. It has the advantage of delivering large DNA fragments into specific genomic locations with attP site, which were generated by the Ballen lab and markered by yellow. Here we are incorporating the P[acman] system with the work from the Basler group which used endogenous PhiC31 source instead of co-injecting the PhiC31 mRNA.

Please visit the Bellen lab for more info:
http://flypush.imgen.bcm.tmc.edu/lab/index.html

FlyC31
In FlyC31 system, a library of landing platforms containing attP site throughout the Drosophila genome were created by the Basler group, which are ready for the transgenesis of the construct with attB site. These landing platforms were deliberately designed to be manipulated in vivo by Cre/loxP system after transgenesis to get rid of most of the non-necessary sequences and only keep your gene-of-interest flanking with one loxP and one attL site.

Please visit the FlyC31 website for more info:
http://www.frontiers-in-genetics.org/flyc31/


Reference:

Venken KJT, He Y, Hoskins RA, Bellen HJ (2006) PhiC31: a BAC transgenic platform for targeted insertion of large DNA fragments in Drosophila melanogaster. Science 314:1747

Bischof J, Maeda RK, Hediger M, Karch F, Basler K (2007) An optimized transgenesis system for Drosophila using germ-line-specific PhiC31 integrases. PNAS 104:3312


Currently available P[acman] strains at BestGene Inc.

BSC Stock# Genotype Estimated CytoSite Coordinate Eye Color1
97292 PBac{yellow[+]-attP-3B}VK00010 chromosome 2   -
9734 PBac{yellow[+]-attP-9A}VK00015 chromosome 2   Red
9753 PBac{yellow[+]-attP-3B}VK00038 5B8 X:5497935 Red
9726 PBac{yellow[+]-attP-9A}VK00006 19E7 X:20689962 Light Orange
9752 PBac{yellow[+]-attP-3B}VK00037 22A3 2L:1584486 Orange
9731 PBac{yellow[+]-attP-9A}VK00012 25A3 2L:4683203 Light Orange
9723 PBac{yellow[+]-attP-3B}VK00002 28E7 2L:8133094 Red
9724 PBac{yellow[+]-attP-3B}VK00003a 31B1 2L:10220182 Red
9724 PBac{yellow[+]-attP-3B}VK00003b 40A4 2L:21639162 Orange
9730 PBac{yellow[+]-attP-3B}VK00011 40E4 2L:21951742 Red
9733 PBac{yellow[+]-attP-9A}VK00014 43A2 2R:2285107 Orange
9735 PBac{yellow[+]-attP-3B}VK00016 47C4 2R:596343 Orange
9728 PBac{yellow[+]-attP-3B}VK00008 50A3 2R:8443624 Light Orange
9747 PBac{yellow[+]-attP-9A}VK00030 50E1 2R:9203330 Orange
9736 PBac{yellow[+]-attP-9A}VK00018 53B1 2R:11361979 Red
9740 PBac{yellow[+]-attP-9A}VK00022 57F5 2R:16689522 Orange
9722 PBac{yellow[+]-attP-3B}VK00001 59D3 2R:18279750 Orange
97462 PBac{yellow[+]-attP-9A}VK00029 h47-h53 94181 of AABU01002142 -
9748 PBac{yellow[+]-attP-3B}VK00031 62E1 3L:2376116 Orange
9750 PBac{yellow[+]-attP-3B}VK00033 65B2 3L:6402205 Red
97542 PBac{yellow[+]-attP-3B}VK00039 67E4 3L:10463229 -
9737 PBac{yellow[+]-attP-9A}VK00019 68D2 3L:11654656 Red
9741 PBac{yellow[+]-attP-9A}VK00023 70A2 3L:13170566 Red
9751 PBac{yellow[+]-attP-3B}VK00036 70C4 3L:13802829 Red
9725 PBac{yellow[+]-attP-9A}VK00005 75B1 3L:17900987 Orange
9732 PBac{yellow[+]-attP-9A}VK00013 76A2 3L:19153237 Red
9739 PBac{yellow[+]-attP-9A}VK00021 76C5 3L:19713047 Orange
9727 PBac{yellow[+]-attP-3B}VK00007 82A1 3R:81372 Orange
9749 PBac{yellow[+]-attP-3B}VK00032 85A2 3R:4301078 Light Orange
9755 PBac{yellow[+]-attP-3B}VK00040 87B10 3R:8265934 Red
9744 PBac{yellow[+]-attP-9A}VK00027 89E11 3R:12878600 Red
9745 PBac{yellow[+]-attP-9A}VK00028 92F1 3R:16375389 Orange
9743 PBac{yellow[+]-attP-9A}VK00026 96F3 3R:21662155 Light Orange
9738 PBac{yellow[+]-attP-9A}VK00020 99F8 3R:26368401 Orange
97422 PBac{yellow[+]-attP-9A}VK00024 102A3 4:79131 -
1Eye colors were determined three days after eclosion (heterozgous state)
2These lines were very hard to transform

Currently available FlyC31 strains at BestGene Inc.

BSC Stock# Genotype Estimated CytoSite Eye Color3
23648 M{3xP3-RFP.attP}ZH-86Fb (with M{vas-int.B}ZH-102D) 86F Orange
23647 M{3xP3-RFP.attP}ZH-102D (with M{vas-int.B}ZH-86Fb) 102D Red
24480 M{3xP3-RFP.attP'}ZH-2A (with M{vas-int.Dm}ZH-102D) 2A Orange
24482 M{3xP3-RFP.attP'}ZH-51C (with M{vas-int.Dm}ZH-2A) 51C Light Orange
24483 M{3xP3-RFP.attP}ZH-51D (with M{vas-int.Dm}ZH-2A) 51D Red
24484 M{3xP3-RFP.attP}ZH-58A (with M{vas-int.Dm}ZH-2A) 58A Light Orange
24485 M{3xP3-RFP.attP'}ZH-68E (with M{vas-int.Dm}ZH-2A) 68E Light Orange
244864 M{3xP3-RFP.attP'}ZH-86Fa (with M{vas-int.Dm}ZH-2A) 86F Red
24487 M{3xP3-RFP.attP'}ZH-96E (with M{vas-int.Dm}ZH-2A) 96E Orange
24488 M{3xP3-RFP.attP}ZH-102D (with M{vas-int.Dm}ZH-2A) 102D Red
3according to FlyC31 website
4BSC#24486 is the weakest strain (low survival rate after injection)